Derek Archila
Stock Analyst at Wells Fargo
(3.25)
# 962
Out of 4,810 analysts
176
Total ratings
41.38%
Success rate
1.29%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $9.82 | +154.58% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $62.09 | +46.56% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.12 | +167.86% | 10 | Apr 1, 2025 | |
| SEPN Septerna | Maintains: Equal-Weight | $14 → $11 | $6.29 | +74.88% | 3 | Mar 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $11 → $10 | $4.43 | +125.73% | 5 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $60 → $26 | $7.58 | +243.01% | 5 | Mar 12, 2025 | |
| QTTB Q32 Bio | Maintains: Equal-Weight | $16 → $15 | $2.02 | +644.42% | 2 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $723 → $741 | $605.38 | +22.40% | 11 | Feb 28, 2025 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $36 | $36.54 | -1.48% | 3 | Feb 24, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $40 → $51 | $18.10 | +181.77% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.27 | +372.44% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $10.94 | +27.97% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.11 | +118.98% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $70 | $58.46 | +19.74% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $15.47 | +190.98% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.19 | +908.40% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $12.80 | +110.94% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $2.23 | +482.96% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $38 → $57 | $25.46 | +123.88% | 7 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $1.99 | +1,109.07% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $30 | $18.97 | +58.14% | 10 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $151 | $81.45 | +85.39% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.99 | +468.56% | 1 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $153.92 | +87.76% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $1.11 | +890.99% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $18.37 | +101.42% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $1.54 | +549.35% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.00 | +1,908.64% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.40 | +429.10% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.69 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $23.88 | +708.21% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $84.16 | -51.28% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $24 → $8 | $9.81 | -18.45% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $7.35 | +716.33% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.37 | +563.62% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.92 | +2,504.17% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $10.75 | +374.42% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $25.06 | +251.16% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.88 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $13.60 | - | 2 | Aug 3, 2017 |
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $9.82
Upside: +154.58%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $62.09
Upside: +46.56%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.12
Upside: +167.86%
Septerna
Mar 28, 2025
Maintains: Equal-Weight
Price Target: $14 → $11
Current: $6.29
Upside: +74.88%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.43
Upside: +125.73%
Arvinas
Mar 12, 2025
Maintains: Overweight
Price Target: $60 → $26
Current: $7.58
Upside: +243.01%
Q32 Bio
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $2.02
Upside: +644.42%
argenx SE
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $605.38
Upside: +22.40%
Exelixis
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $36.54
Upside: -1.48%
AnaptysBio
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $18.10
Upside: +181.77%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.27
Upside: +372.44%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $10.94
Upside: +27.97%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.11
Upside: +118.98%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $68 → $70
Current: $58.46
Upside: +19.74%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $15.47
Upside: +190.98%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.19
Upside: +908.40%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $12.80
Upside: +110.94%
Dec 11, 2024
Maintains: Overweight
Price Target: $15 → $13
Current: $2.23
Upside: +482.96%
Dec 2, 2024
Upgrades: Overweight
Price Target: $38 → $57
Current: $25.46
Upside: +123.88%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $1.99
Upside: +1,109.07%
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $43 → $30
Current: $18.97
Upside: +58.14%
Oct 31, 2024
Maintains: Overweight
Price Target: $153 → $151
Current: $81.45
Upside: +85.39%
Oct 4, 2024
Initiates: Overweight
Price Target: $17
Current: $2.99
Upside: +468.56%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $153.92
Upside: +87.76%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $1.11
Upside: +890.99%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $18.37
Upside: +101.42%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $1.54
Upside: +549.35%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.00
Upside: +1,908.64%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.40
Upside: +429.10%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.69
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $23.88
Upside: +708.21%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $84.16
Upside: -51.28%
Mar 31, 2020
Maintains: Hold
Price Target: $24 → $8
Current: $9.81
Upside: -18.45%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $7.35
Upside: +716.33%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.37
Upside: +563.62%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.92
Upside: +2,504.17%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $10.75
Upside: +374.42%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $25.06
Upside: +251.16%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.88
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $13.60
Upside: -